Impact of COVID-19 on STEMI: Second youth for fibrinolysis or time to centralized approach?

Gabriele Tumminello *, Lucia Barbieri, Stefano Lucreziotti, Domitilla Gentile, Barbara Conconi, Marco Centola, Antonio Mafrici, Stefano Carugo

Cardiology Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

ARTICLE INFO

Article history:
Received 17 May 2020
Received in revised form 26 June 2020
Accepted 18 July 2020
Available online 23 July 2020

Keyword:
COVID-19
STEMI therapy

ABSTRACT

On March 11th 2020 the World Health Organization declared the pandemic infection of SARS-CoV-2 (COVID-19) and Italy was one of the most affected country. The regional Emergency Medical System (EMS) founded itself facing an exponential increase in hospitalizations with a consequent organizational system crisis. Experts from China, UK and US suggested to reconsider thrombolysis as the best treatment in term of balance between time consumption and operators safety for ST-segment elevation myocardial infarction (STEMI) patients respect to primary PCI (pPCI). The system reorganization consisted in a centralization of all the emergency nets: from 55 hospitals with cardiac catheterization laboratories distributed within our region offering a 24/7 service we passed to 13 Hub and 42 Spoke centres. Dedicated in-hospital paths for patients COVID positive or suspected (pCOV+) and COVID negative (pCOV−) were instituted. We analysed all consecutive patients undergoing emergency coronary angiogram from March 14 to April 14, 2020 at San Carlo Hospital in Milan comparing the two different in-hospital paths. We collected 30 STEMI patients. Eighteen patients (60%) were treated in pCOV−, while twelve patients (40%) in pCOV+. No significant differences were found among the two groups regarding key time points of STEMI care and interestingly we didn't find any treatment delay in pCOV+. In conclusion, a focused overhaul of the EMS may allow to maintain pPCI as the treatment of choice for patients and operators.

1. Introduction

On March 11th 2020 the World Health Organization (WHO) declared the pandemic infection of SARS-CoV-2 (COVID-19). Italy was one of the most affected countries reaching 159,916 confirmed cases with 20,465 death (WHO data Report-85 April 14th 2020). Our regional Emergency Medical System (EMS) net was reorganized dividing the 55 hospital equipped with cardiac catheterization laboratories offering 24/7 service in to 13 Hub and 42 Spoke centres in order to centralize the resources. In ST-segment elevation myocardial infarction (STEMI) primary percutaneous coronary intervention (pPCI) is to date the recommended therapy [1] if the estimated time is ≤120 min from the diagnosis, otherwise fibrinolytic therapy must be preferred. Considering the dramatic impact of COVID-19 on emergency services, experts from China, UK and US proposed to reconsider fibrinolytic therapy as a first-choice approach [2,3] thanks to the better balance between systems delays and workforce protection.

2. Material and methods

Our population is represented by consecutive STEMI patients undergoing emergency coronary angiography from March 14 to April 14, 2020 at San Carlo Hospital in Milan, HUB center according to EMS network reorganization. Patients were divided in 2 groups (suspected /defined and low probability/no evidence of Covid-19) at the first medical contact according to presence of at least one of the following: recent history of fever, dyspnea, cough, fatigue, gastrointestinal symptoms and contact with Covid-19 cases. All cardiac arrests were treated as suspected. The defined diagnosis of SARS-COV-2 was performed by nasal swab test immediately after pPCI. Two distinct in-hospital paths (pCOV+ and pCOV−) were identified with two different cath labs, setted up with adequate protective personal equipment (PPE). Clinical data and main time components of STEMI care were collected for all patients. The protocol was performed in accordance to the Declaration of
Helsinki statements as requested by our local Ethical Committee; all the data were collected anonymously; all the patients subscribe a disclosure statement routinely for the use of personal data at the beginning of hospitalization.

All categorical variables were expressed by percentage, while continuous variables were expressed by mean ± standard deviation (M-SD).

### 3. Results

We analysed a total of 30 patients, 70% male, with a mean age of 64 ± 11.7 years. Clinical and demographic characteristics are: diabetes 15.8%, hypertension 36.4%, family history of coronary artery disease 13.6%, active smoke 20.5%, dyslipidaemia 9.1%, previous PCI 2.3%, previous myocardial infarction 4.5%, chronic obstructive pulmonary disease 4.5%. The first medical contact was in most cases (73.3%) with the physicians of EMS out of hospital or in the emergency department (20%). In only two cases patients were already hospitalized: one in our HUB center and the in a Spoke distant 8.2 Km from our hospital. The maximum distance planned for Spoke centers was 25 km. In 73.3% STEMI diagnosis was made in pre-hospital setting and anterior STEMI was the most represented (44.8%). Eighteen patients (60%) were treated in pCOV, while twelve patients (40%) in pCOV+. For seven (58.3%) patients of the pCOV+ COVID-19 diagnosis was confirmed, while, among pCOV−twelve patients (66.7%) resulted negative, one (5.6%) was positive and five (27.8%) were not tested. No significant differences were found among the two groups regarding key time points of STEMI care (Table 1), in particular regarding STEMI diagnosis-to-balloon and door-to-balloon times below the limits for the consideration of a fibrinolytic therapy. In favour of this strategy there is also the fact that the real risk related to fibrinolysis in the setting of COVID-19 infection, due to secondary coagulation alterations, is not well defined [4].

### 5. Limitations

The sample size is too small to draw definite conclusion but are in line with recent editorial guidelines [5]. Data are referred to a specific geographical and logistic region where the public sanitary system is well developed and distances are limited. These two factors may adversely affect the results in other world regions.

### 6. Conclusion

While a blanket policy of pPCI during a pandemic condition might be not the right choice when applied to the usual organizational system, a complete and focused overhaul of the EMS and STEMI pathways as the one here described may allow to maintain pPCI as the treatment of choice for patients.

### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### References

[1] B. Ibanez, S. James, S. Agewall et al., ESC Scientific Document Group, 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC), Eur. Heart J. 39(2) (2018) 119–177.

[2] T. Chor-Cheung Frankie, C. Kent-Shek, L. Simon et al., Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China, Circ. Cardiovasc. Qual. Outcomes 2020 Mar 17:CIRCOUTCOMES120006631. doi: 10.1161/CIRCOUTCOMES.120.006631 [Epub ahead of print].

[3] J.D. Matthew, G.C. Mauricio, A. Anthony, J.K. Dharam, Reperfusion of STEMI in the COVID-19 Era – Business as Usual? 10.1161/CIRCULATIONNAHA.120.047122.

[4] R.L. Medcalf, C.B. Keragala, P.S. Myles, Fibrinolysis and COVID-19: a plasmin paradox, J. Thromb. Haemost. 2020 Jun 16, doi: 10.1111/jth.14960. Online ahead of print.

[5] E. Mahmud, H.L. Dauerman, F.G.P. Welt, J.C. Messenger et al., Management of acute myocardial infarction during the COVID-19 pandemic a consensus statement from the society for cardiovascular angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP), Catheter Cardiovasc Interv. 2020 Apr 20. doi: 10.1002/ccd.28946. Online ahead of print.